Team Rapid Novor Team will be exhibiting at the 17th Annual Discovery on Target meeting hosted at Westin Copley Place in Boston, Massachusetts. You can find us at our exhibit booth #408! Our Business Development Manager, Anthony, and our Scientific Sales Executive, Jennifer, will be at the booth showing off how our de novo protein [...]
Q: What antibody species can you sequence? A: All of them! We are able to sequence any species because we use de novo protein sequencing by tandem mass spectrometry (MS/MS). This type of protein sequencing by mass spectrometry does not rely on existing databases that might introduce bias or wrong amino acid calls . In [...]
Q: Under what shipping conditions should I send my protein sample? A: We suggest the following shipping conditions: We recommend that you ship your samples either lyophilized or in solution. If your samples are already lyophilized it is best to ship them to us in that form, they can be shipped at ambient temperatures, [...]
Q: How much protein and what purity is needed for protein sequencing? A: We typically accept samples at 100 µg with at least 80% purity, rare in the field. To measure the amount of protein, you can use a microvolume spectrophotometer such as the Nanodrop or a traditional Bradford assay. To assess purity of [...]
Overview Introduction Sample preparation for complete LC-MS/MS sequencing of a pure protein sample differs substantially from the preparation used for protein identification in complex samples. To sequence a protein de novo, the experimental design should aim to identify each amino acid (a.a.) multiple times within different peptides, instead of relying on only a few peptides [...]
Q: What are common contaminants that could affect my protein sequencing results? A: Typical contaminants that we see affecting samples are non-target proteins, and non-target antibodies [1, 2, 3]. Protein Contaminants The most common protein contaminants include keratin and serum albumin [1, 2, 3]. Other Mass Spectrometry (MS) protein contaminants identified in research labs worldwide [...]
Frederick Sanger, father of DNA sequencing, sequenced the first protein, insulin, before he began his efforts in deciphering nucleotide codes. Nowadays, DNA sequencing is so popular that it is easy to forget that the first sequenced biological material was protein – insulin, by Sanger [1, 2]. Sanger, and another [...]
Meet Anthony: he likes having a quality meal. Balanced. With healthy fats like avocado. Anthony wakes up every morning to the smell of coffee and a strong sense of carpe diem. He doesn’t just employ the art of positive visualization, popularized by The Sopranos. His dogma, if a TV show’s principles could be dogma, is [...]
This year’s American Society for Mass Spectrometry (ASMS) conference took place in Atlanta, Georgia, the peach state of the US. Our Proteomics Specialist, Kathleen Gorospe, brought back home some delicious peach cookies, for which we have no pictures because they were devoured instantly. The ASMS conference was very fruitful indeed. There was a total of [...]
A Large-Scale Comparison of MS-based Antibody De Novo Protein Sequencing and Targeted DNA Sequencing Introduction The DNA sequences of antibodies are highly diverse due to the V-(D)-J recombination and hypersomatic mutations. As such, a new antibody of interest is unlikely to appear in any existing sequence database. Consequently, the database search approach commonly used in [...]
Learn about what's included in our REmAb™ Service Report, including: notable observations, experiment procedures and sequence confirmations. It's time to remove the guesswork and increase your specificity.
In this video you will learn about the advantages to protein sequencing by mass spectrometry; including the ability to sequence without having access to the original cell line. For more information, check out our resource: De Novo Antibody Protein Sequencing with Mass Spectrometry.
Introduction Monoclonal antibodies (mAbs) are widely used in research, diagnosis, and pharmaceutical purposes. Lately, the relatively lower quality of the research-purpose mAbs is a point of concern within the research community¹,². The problems include the lack of validation and low reproducibility. As most of the validation is done by immunoassay, the extent of protein contamination, [...]